Literature DB >> 26077984

Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer.

Paul R Hutson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077984      PMCID: PMC4583345          DOI: 10.1007/s40262-015-0293-z

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  7 in total

1.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

2.  Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Authors:  Celestia S Higano; Tomasz M Beer; Mary-Ellen Taplin; Eleni Efstathiou; Mohammad Hirmand; David Forer; Howard I Scher
Journal:  Eur Urol       Date:  2015-02-16       Impact factor: 20.096

3.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

4.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

Review 5.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

6.  Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Authors:  Jacqueline A Gibbons; Michiel de Vries; Walter Krauwinkel; Yoshiaki Ohtsu; Jan Noukens; Jan-Stefan van der Walt; Roelof Mol; Joyce Mordenti; Taoufik Ouatas
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

7.  Clinical Pharmacokinetic Studies of Enzalutamide.

Authors:  Jacqueline A Gibbons; Taoufik Ouatas; Walter Krauwinkel; Yoshiaki Ohtsu; Jan-Stefan van der Walt; Vanessa Beddo; Michiel de Vries; Joyce Mordenti
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

  7 in total
  1 in total

1.  Comment on: "Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer".

Authors:  Jacqueline A Gibbons
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.